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Vitamin A analogs (retinoids) suppress oral and lung carcinogenesis in animal models and prevent
the development of second primary tumors in head, neck, and lung cancer patients. These
effects result from changes in the expression of genes that regulate cell growth and
differentiation. Retinoic acid receptors (RARs; -a, -P, and -y) and retinoid X receptors (RXRs; -a, -f,
and, -y) are retinoid-activated transcription factors, which mediate effects of retinoids on gene
expression. Therefore, alterations in receptor expression or function could interfere with the
retinoid signaling pathway and thereby enhance cancer development. We found that the
expression of RAR3 was suppressed in more than 50% of oral and lung premalignant lesions in
individuals without cancer and in dysplastic lesions adjacent to cancer and in malignant oral and
lung carcinomas. The expression of the other receptors was not different among normal,
dysplastic, and malignant oral tissues. However, the expression of RARy and RXR3 was
somewhat decreased in lung cancers. These results show that RARPi expression is lost at early
stages of carcinogenesis in the aerodigestive tract and support the hypothesis that the loss of
RARi expression may facilitate the development of some of these cancers. Environ Health
Perspect 105(Suppl 4):985-988 (1997)




Lung cancer in the United States leads
other cancers in both incidence (17% in
men, 12% in women) and mortality (34%
in men, 22% in women). Head and neck
(HN) cancers account for about 3.2% of
new cancer cases and 2.2% of cancer
deaths (1). Unfortunately, the overall sur-
vival rate among HN cancer patients has
remained unchanged for the last 3 decades
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(approximately 45%) despite adjuvant
chemotherapy (2). The situation with lung
cancer is more grim because ofthe severe
morbidity and mortality and the discourag-
ing 15% overall 5-year survival rate, which
has not been improved despite advance-
ments in treatment modalities (3,4).
Smoking tobacco is a major risk factor for
developing HN and lung cancer (2-4) and
even ex-smokers continue to be at a higher
risk for more than 10 years (5). The expo-
sure to carcinogenic substances and pro-
moters in tobacco smoke leads to genetic
changes over large areas ofthe oral cavity
and the airway epithelium, resulting in a
"field cancerization" with potential multi-
focal unsynchronized premalignant and
primary malignant lesions (6,7). This may
explain the high recurrence rate and the
development of second primary tumors
following resection ofearly stage (I or II)
HN and lung cancers (2,8). Thus novel
approaches to control cancers of the
aerodigestive tract should include treat-
ment ofsurrounding "condemned" airway
epithelium. Because these cancers develop
over a prolonged period of exposure to
carcinogens and promoters and because of
the multistep nature of carcinogenesis,
there is an opportunity to intervene in the
process using chemical agents for
prevention, termed chemoprevention (9).
Indeed, chemoprevention with retinoids
(vitamin A analogs) is now being exam-
ined for its potential to reduce the inci-





Epidemiological studies have shown that
vitamin A deficiency is associated with
increased incidence of lung cancer (10).
Vitamin A deficiency also induces squa-
mous metaplasia in the mucosa of the
upper aerodigestive tract (14) that is simi-
lar to premalignant changes in the mucosa
in heavy smokers (15). Vitamin A supple-
mentation reversed squamous metaplasia
in the trachea from vitamin A-deficient
animals in vivo (16) and various retinoids
exhibited a similar activity in vitro (9).
Furthermore, retinoids inhibited carcino-
genesis in experimental animal models
(17) including a model for oral cancer
(18), suppressed premalignant oral lesions
(e.g., leukoplakia) (8,11,13), and also pre-
vented the development of second pri-
mary tumors in HN cancer patients
(8,12) and in lung cancer patients (19).
The association between vitamin A status
and cancer development in the upper air-
ways and the ability of retinoids to sup-
press premalignant lesions suggest that
physiological levels of retinoids are
required for a natural anticarcinogenesis
surveillance mechanism and that retinoid-
dependent signaling pathways play a role
in suppression of carcinogenesis. This
hypothesis implies that abnormalities in
retinoid levels or in their signal transduc-
tion pathway could enhance carcinogene-
sis and that pharmacological levels of
retinoids might activate the signaling
mechanisms even in abnormal cells.
Mechanisms of
Retinoid Action
We have shown that retinoids suppress the
proliferation ofhead and neck squamous
cell carcinoma (HNSCC) cells in monolayer
cultures, inhibit the formation ofsquamous
cell carcinoma colonies in semisolid agarose
or Matrigel (Collaborative Biomedical
Products, Bedford, MA) and decrease the
growth ofHNSCC multicellular spheroids
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(20-27). In addition, retinoids suppress
the expression ofsquamous differentiation
markers (e.g., involucrin, type I transgluta-
minase, keratin KI, cholesterol sulfate,
and others) and inhibit cornified envelope
formation in HNSCCs (22,24,26,28).
It is thought that the anticarcinogenesis
and antitumor effects of retinoids are the
result of retinoid-induced changes in cell
growth and differentiation resulting from
changes in the expression ofspecific genes
such as oncogenes, growth factors, and
growth factor receptors (29). Retinoids
exert most of their effects on gene ex-
pression by activating a signal transduc-
tion pathway in which nuclear retinoid
receptors play a pivotal role (30-34).
These receptors are members of the
steroid hormone receptor superfamily.
Two types of receptors have been identi-
fied: retinoic acid (RA) receptors (RARs)
and retinoid X receptors (RXRs). Each
type ofreceptor includes three subtypes-
a, 3, and y-with distinct amino- and
carboxy-terminal domains. The RARs
bind all-trans-RA (ATRA) and 9-cis-RA
(9cRA), a natural RA isomer, whereas the
RXRs bind only 9cRA (30-34). RARs
form heterodimers with RXRs, bind to
specific DNA sequence-RA response ele-
ments (RAREs)-characterized by direct
repeats of (A/G)GGTCA separated by
two or five nucleotides, and act as ligand-
dependent transcriptional regulators for
RA-responsive genes (30,32). Because
each subtype exhibits distinct patterns of
expression during embryonal development
and different distributions in adult tissues,
each is thought to regulate the expression
ofa distinct set ofgenes as well as a com-
mon set ofgenes (30-34). We found that
normal buccal mucosa specimens (35)
and HNSCC cell lines express RARa,
RARP, RARy, RXRa, and RXRP (26)
and that the RARP levels were lower in
more squamous differentiated cells (26).
Several isoforms ofRAR4 mRNA that
are transcribed from two different promot-
ers have been identified and RAR32 was
found to be the major isoform in RA-
treated cells (36). This receptor is expressed
constitutively in a limited variety ofcells;
however, its expression is increased in
response to RA in many cell types (37).
This ligand-dependent induction is due to
the presence of an RARE (RAREf2,
GGTTCAccgaaAGTTCA) that binds
RXR-RAR heterodimers preferentially in
the RARP gene promoter and mediates
ligand-dependent transcriptional activation
ofthe RAR,B2 gene (30-34,38).
Aberrations in Retinoid
Receptor Expression
Nuclear retinoid receptors are the proximate
mediators ofmany ofretinoids' effects on
gene expression. Therefore, it is plausible
to assume that changes in their expression
and function may cause aberrations in the
response ofcells to retinoids and thereby
alter the regulation ofcell growth, differen-
tiation, and expression ofthe transformed
phenotype. This assumption makes investi-
gations of the expression patterns of
retinoid receptors in normal, premalignant,
and malignant tissues very timely in that
they may provide important clues to the
roles ofthese receptors in cancer develop-
ment and the response of these tissues to
retinoid treatment.
In Vihv
Some indications that abnormalities in
receptor expression exist have come from
studies of lung cancer cell lines. It was
found that whereas most human lung car-
cinomas cell lines express RARa, RAR'y,
and RXRa constitutively, the expression of
RARI is suppressed in many of the cell
lines (39-42). Because the normal coun-
terparts ofthese cancer cells in the lung tra-
cheobronchial epithelium and in the
nonkeratinizing oral cavity mucosa express
RAR,B mRNA, it was concluded that the
selective suppression of the expression of
RARPi may be related to the process of
malignant transformation in epithelial cells
(39-42). Support for this contention was
provided by the report that lung carci-
noma cells expressing a transfected RARP
exhibited decreased tumorigenicity in
nude mice (43). The abnormalities in
RAR,B expression suggested that this recep-
tor may be involved in the pathogenesis of
lung cancer (39,40). Similarly, RARi
expression decreased in several human
HNSCC cell lines (44).
The mechanism underlying the lack of
expression ofthe RARI gene is not known.
There appear to be no homozygous dele-
tions or rearrangements of the gene as
indicated by southern blotting of DNA
from HNSCC cell lines that do not express
the RAR, mRNA (44), and studies with
HeLa cells suggest that the loss of RAR
expression was not caused by mutations in
the RARE or otherproximal regulatoryele-
ments of the RARP promoter (45).
Another possibility is aberrant transcrip-
tion ofthe RARi gene as reported for lung
cancer cells by others (46) and for
HNSCC cells by our group (38). These
studies have demonstrated that reporter
gene constructs containing 5'-flanking
sequences of the native RARP gene pro-
moter fused upstream ofthe luciferase cod-
ing region could not be activated
effectively in some HNSCC or lung cancer
cells byeitherATRA or 9cRA treatment.
In Vivo
The RARP gene is located on chromosome
3p24 close to a region that is often deleted
in HN and lung cancer. However,
rearrangements or deletions of the RARI
gene were not detected in several surgical
specimens oflung cancer (39). Thus the
molecular mechanism underlying the rela-
tionship between aberrant expression of
RARP and the development oflung cancer
is still unknown. We studied specimens
from human HN and lung premalignant
and malignant tissues by a nonradioactive
in situ hybridization method that we
adapted for the analysis ofreceptor expres-
sion in formalin-fixed, paraffin-embedded
surgical specimens (47). To determine
whether the expression of the receptors'
mRNAs is related to the development of
HNSCC, we used digoxigenin-labeled
antisense riboprobes ofRARa, -P, -y, and
RXRa and -P for in situ hybridization to
histological sections of specimens from
seven normal volunteers and 31 HNSCC
patients. All 31 tissue specimens from
HNSCC patients contained carcinomas;
16 also contained dysplastic lesions, 22 also
contained hyperplastic lesions, 17 also con-
tained adjacent normal tissue, and 6 con-
tained all four types oftissue. All specimens
from normal volunteers expressed the five
receptors. Similar levels of RARy, RXRa,
and RXRP mRNAs were detected in most
of the adjacent normal, hyperplastic, dys-
plastic, and malignant tissues. RARa
mRNA was detected in 94% ofadjacent
normal and hyperplastic tissues and in
87% ofdysplasias and 77% of HNSCCs.
In contrast, RARP mRNA was detected in
about 70% ofadjacent normal and hyper-
plastic lesions, and its expression decreased
further to 56% ofdysplastic lesions and
35% ofHNSCCs. The difference in RARP
level in carcinoma and adjacent normal tis-
sues was significant (48). Similar studies
with specimens from normal lung (n= 17)
and non-small cell lung cancers (NSCLC)
(35 adeno- and 37 squamous cell carcino-
mas) revealed that 89% of normal speci-
mens expressed RARP. In contrast, only
about 50% of dysplastic tissues and
NSCLC expressed this receptor's mRNA
(49). These results indicate that the
decreased expression ofRARJ3 occurs in
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dysplastic lesions and may be associated
with HN and lung cancer development.
To determine whether the decrease in
RARP can be detected in premalignant
lesions from patients without cancer, we
examined the expression ofnuclear retinoid
receptors in specimens from normal oral
mucosa (n=7) and in specimens from oral
premalignant lesions before (n= 52) and
after (n=39) a 3-month treatment with 13-
cis-retinoic acid (13cRA). All normal speci-
mens expressed RARI. In contrast, RARI
mRNA was detected in only 21 of 52 oral
premalignant lesions. The suppression of
RAR,B expression in the premalignant
lesions was significant (p=0.003). Thirty-
five ofthe 39 specimens available after treat-
ment expressed RARP. The increase in
expression was significant (p<0.00001). All
normal and premalignant specimens
expressed similar levels ofRARa and RARy
and RXRs -a, -j, and -y. Eighteen of 22
cases (82%) in which RAR[ level increased
responded clinically to 13cRA (35). These
results show that a selective loss ofRARP
mRNA expression occurs at early stages of
oral carcinogenesis and demonstrate that
RARP can be upregulated by 13cRA in
humans. Furthermore, the association
between the increase in RAR,B expression
and clinical response suggests that RARf
has a role in mediating retinoid response.
RAR,B expression may depend on the cellu-
lar level ofretinoids because this receptor's
gene contains an RARE in the 5' region and
is inducible by retinoids (37). This conclu-
sion is supported by the finding that RARJ3
expression is selectively reduced in several
organs during vitamin A deficiency and
enhanced by retinoic acid, as demonstrated
in studies with rats (50,51). Although it is
unlikely that people in the United States are
vitamin A deficient due to severe malnutri-
tion or other causes, one cannot exclude the
possibility that some premalignant tissues
are vitamin A deficient. Indeed, we have
demonstrated recently that monoclonal
antibody (MAb) against ATRA bound to
100% of normal oral tissue (n= 7) com-
pared to only 20 of43 premalignant oral
lesions. Similarly, 7 of7 normal specimens
contained RAR,B mRNA compared to only
14 of43 premalignant oral lesions. Twenty-
four specimens were available before and
after a 3-month treatment with 13cRA in
vivo. Anti-RA-MAb binding to these speci-
mens increased from 10 of24 before to 22
of24 after treatment and the expression of
RARf mRNA increased from 7 of24 before
to 21 of 24 after treatment, respectively.
There was a strong agreement between the
binding ofanti-RA-MAbs and the expres-
sion ofRARP (52). Thus, we propose the
binding anti-RA-MAbs reflects the level of
retinoids in the tissues and that this level is
related strongly to RARf expression.
Conclusions
The results serve as the basis for the follow-
ing hypotheses. First, RARP plays a role in
suppression of carcinogenesis; thus the
downregulation ofRARP enables prema-
lignant cells to escape the anticarcinogenic
activity ofphysiological levels ofretinoids.
Second, at pharmacological doses, some
retinoids can overcome the resistance of
certain premalignant and malignant cells
to the effects of retinoids by mechanisms
that may include an increase in RAR,
level. Third, RARP may be a useful inter-
mediate marker in HN carcinogenesis pre-
vention studies because its expression is
decreased in early stages of carcinogenesis
and its expression is induced in vivo dur-
ing treatment with 13cRA, and this
increase in vivo is associated with response
to the preventive agent.
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